Monday, Dec 18, 2017
Kevin Mahn
president/chief investment officer, Hennion & Walsh Asset Management
The Big Interview
On Twitter: @HennionandWalsh
Links: www.hennionandwalsh.com
Monday, Dec 18, 2017
Steve Wood
chief market strategist, Russell Investments
The Big Interview
On Twitter: @Russell_Invest
Links: www.russellinvestments.com/us; https://russellinvestments.com/us/insights/global-market-outlook
Monday, Dec 18, 2017
Heather Lord
strategy & innovation director, Capital Group
The Survey Says
On Twitter: @AmericanFunds
Links: americanfunds.com; https://www.capitalgroup.com/content/dam/cgc/shared-content/documents/reports/03_FF_1602371_PR%20Wisdom%20of%20Experience%20Part%203%20REPORT.pdf
Friday, Dec 15, 2017
John Cole Scott
chief investment officer, Closed-End Fund Advisors
MoneyLife Market Call
On Twitter: @JohnColeScott
Links: cefadvisors.com; cefdata.com
Friday, Dec 15, 2017
Tim Freundlich
Friday, Dec 15, 2017
Maura Cassidy
Friday, Dec 15, 2017
Jeff Williams
lead trader, PennyPro.com
A Thought for Your Pennies
On Twitter: @thePennyPro
Tickers Discussed :ZSAN
Links: pennypro.com; ragingbull.com
Thursday, Dec 14, 2017
Garvin Jabusch
portfolio manager, Green Alpha Advisors
MoneyLife Market Call
On Twitter: @AlphaVerde; @Garvin1313
Tickers Discussed :JKS, FSLR; during "Hold It or Fold It:" DAR, XYL, PEGI, BABA, GOOG
Links: greenalphaadvisors.com
Thursday, Dec 14, 2017
Jeff Davis
chief investment officer, LMCG Investments
The Big Interview
Links: www.LMCGfunds.com; www.LMCG.com
DetailInformation: Jeff Davis of LMCG Investments in Boston said he expects the stock market to get a weak start to the new year for technical reasons, and says that investors need to brace themselves for a correction that he sees as inevitable
Thursday, Dec 14, 2017
Kyle Dennis
co-founder/director, BioTech Breakouts
Biotech Breakout of the Week
On Twitter: @kylewdennis; @RagingBull
Tickers Discussed :SMMT
Links: Www.biotechbreakouts.com; www.ragingbull.com
DetailInformation: Kyle Dennis of BiotechBreakouts.com says that Summit Therapeutics (SMMT) is worth looking at now ahead of a Phase 2 data release scheduled for the first quarter of 2018 on a drug treatment for Duchenne muscular dystrophy. Dennis noted that while the condition is rare, a successful trial for another Duchenne drug helped to move Sarepta Therapeutics recently. Dennis is expecting Summit -- which he says is a buy now priced between $10 and $10.50 per share -- to reach $13 to $14 by year's end.